| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 0 | 1.670 | 6.582 | 3.726 | 7.334 | 5.092 | 708 | 2.028 | 142 | 0 |
| Total Income - EUR | 102.375 | 94.230 | 38.756 | 45.509 | 50.828 | 33.346 | 26.993 | 35.871 | 28.465 | 11.660 |
| Total Expenses - EUR | 101.946 | 93.885 | 35.862 | 44.286 | 48.243 | 33.182 | 30.628 | 35.694 | 30.955 | 16.374 |
| Gross Profit/Loss - EUR | 430 | 344 | 2.894 | 1.224 | 2.585 | 164 | -3.635 | 177 | -2.491 | -4.714 |
| Net Profit/Loss - EUR | 430 | 328 | 2.801 | 1.224 | 2.513 | 113 | -3.643 | 157 | -2.492 | -4.714 |
| Employees | 4 | 3 | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 |
Check the financial reports for the company - Pharmacorp Innovation Srl
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 7.207 | 7.176 | 6.892 | 11.595 | 12.389 | 10.777 | 10.249 | 9.722 | 10.550 | 10.129 |
| Current Assets | 22.059 | 19.130 | 18.590 | 11.243 | 4.944 | 8.301 | 6.181 | 8.111 | 7.437 | 7.236 |
| Inventories | 17.604 | 11.279 | 11.089 | 8.876 | 4.710 | 6.069 | 5.935 | 5.953 | 6.198 | 6.163 |
| Receivables | 0 | 1.670 | 0 | 519 | 0 | 2.007 | 0 | 2.028 | 1.011 | 1.005 |
| Cash | 4.455 | 6.181 | 7.502 | 1.848 | 235 | 225 | 246 | 131 | 228 | 67 |
| Shareholders Funds | 4.256 | 4.621 | 7.344 | 8.433 | 10.783 | 10.692 | 6.813 | 6.991 | 4.477 | -262 |
| Social Capital | 225 | 303 | 298 | 292 | 287 | 281 | 275 | 276 | 275 | 273 |
| Debts | 15.948 | 21.685 | 18.138 | 14.405 | 6.550 | 8.386 | 9.617 | 10.842 | 13.510 | 17.627 |
| Income in Advance | 9.061 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "7210 - 7210" | |||||||||
| CAEN Financial Year |
7211
|
|||||||||
Comments - Pharmacorp Innovation Srl